Results 281 to 290 of about 59,758 (308)

Tackling multi-drug resistant fungi by efflux pump inhibitors

Biochemical Pharmacology
The emergence of multidrug-resistant fungi is of grave concern, and its infections are responsible for significant deaths among immunocompromised patients. The treatment of fungal infections primarily relies on a clinical class of antibiotics, including azoles, polyenes, echinocandins, polyketides, and a nucleotide analogue.
Kritika Engle, Gautam Kumar
openaire   +2 more sources

Polymeric Efflux Pump Inhibitors in Oral Drug Delivery

American Journal of Drug Delivery, 2006
Drug efflux pump transporters of the ATP-binding cassette family such as P-glycoprotein and multidrug resistance proteins 1 and 2 are believed to confer multidrug resistance to tumor cells and affect overall absorption, distribution, metabolism, and elimination of orally administered clinically important therapeutic substances.
Andreas Bernkop-Schn??rch, Vjera Grabovac   +1 more
openaire   +1 more source

Microbial Efflux of Antibiotics and Inhibitors of Efflux Pumps

2014
Detergent-like bile salts kill bacterial cells by destroying bacterial multidrug resistance (MDR) efflux systems. These not only play an important role in antibacterial resistance but also contribute to bacterial pathogenesis. Reserpine and H+/K+ ATPase inhibitors can significantly reduce MICs, increase killing activity, and prolong the postantibiotic ...
openaire   +1 more source

ปั๊มขับยาปฏิชีวนะและสารยับยั้ง Antibiotic Efflux Pumps and Inhibitors

มค.-ธค., 2, ไทยไภษัชยนิพนธ์
openaire   +1 more source

The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies

Ca-A Cancer Journal for Clinicians, 2022
Sharon Elad, Noam Yarom, Yehuda Zadik
exaly  

Natural Product as Efflux Pump Inhibitors Against MRSA Efflux Pumps: An Update

2022
Pallavi Ahirrao, Ritu Kalia, Sanjay M. Jachak   +2 more
openaire   +1 more source

Trends in kinase drug discovery: targets, indications and inhibitor design

Nature Reviews Drug Discovery, 2021
Misty M Attwood, Stefan Knapp
exaly  

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Nature Medicine, 2022
Adriaan A Voors, Christiane Angermann Angermann, John R Teerlink   +2 more
exaly  

The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment

Nature Reviews Clinical Oncology, 2023
Nicholas Turner
exaly  

Bacterial Drug Efflux Pump Inhibitors from Plants

2022
Armel Jackson Seukep, Christophe Dongmo Fokoua-Maxime, Hélène Gueaba Mbuntcha, Guilin Chen, Jules Clément Nguedia Assob, Martin Tenniswood, Satyajit Dey Sarker, Victor Kuete, Guo Ming-Quan   +8 more
openaire   +1 more source